SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 27, 2012
BIOCUREX, INC.
---------------------------------
(Name of Small Business Issuer in its charter)
Texas 000-269947 75-2742601
------------------ ----------------- --------------
(State of incorporation) (Commission File No.) (IRS Employer
Identification No.)
7080 River Road, Suite 215
Richmond, British Columbia
Canada, V6X 1X5
--------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (866) 884-8669
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in
Fiscal Year.
On July 31, 2012 the shareholders of the Company approved, at a special
meeting, an amendment to the Company's Certificate of Incorporation authorizing
a reverse split of the Company's outstanding common stock on a basis of up to
1-for-150. The exact ratio of the reverse stock split was to be determined by
the Company's board of directors. On October 2, 2012 the Company's directors
authorized the reverse stock split on a 1-for-150 basis.
An amendment to the Company's Certificate of Incorporation pertaining to
the reverse split was filed with the Texas Secretary of State on November 27,
2012.
The stock split will become effective in the over-the-counter market when
FINRA announces the effective date of stock split.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 4, 2012 BIOCUREX, INC.
By: /s/ Ricardo Moro
---------------------------------------
Dr. Ricardo Moro, Chief Executive
Officer
